



25th September 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Grant of Certificate of Suitability (CEP) for Fenofibrate - Process II

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the **European Directorate for the Quality of Medicines & HealthCare (EDQM)** has granted a **Certificate of Suitability (CEP)** on **24th September 2026** for the Company's Active Pharmaceutical Ingredient (API) product **"FENOFIBRATE – Process II"**.

The aforesaid CEP is in addition to the existing valid CEP held by the Company for **"Fenofibrate"**.

Process II has been developed by the Company to cater the specific process and requirements of its customers.

The grant of the CEP further strengthens the Company's regulatory portfolio and supports its ability to cater the regulated markets for Fenofibrate.

Details required under abovesaid SEBI Master Circular is annexed herewith as **"Annexure -1"**.

This information will also be accessible on the Company's website: www.iolcp.com.

You are requested to take the above information on record.

Thanking You,

Yours faithfully,

for **IOL Chemicals and Pharmaceuticals Limited**

Abhay Raj Singh

Sr. Vice President & Company Secretary



Annexure -1

Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is annexed herewith

Particulars	Details
a) Name of the regulatory or licensing authority	European Directorate for the Quality of Medicines & HealthCare (EDQM)
b) Brief details of the approval/license obtained	Certificate of Suitability (CEP) for “ FENOFIBRATE - Process II ”. This is in addition to the existing CEP held by the Company for “FENOFIBRATE”.
c) Impact/relevance of such approval/license to the listed entity	The approval strength the Company's regulatory compliance and facilitates the supply of FENOFIBRATE – Process II in regulated markets.
d) Withdrawal/cancellation or suspension of the approval/license	Not applicable.
e) Period for which such approval/license is/was valid	The CEP is valid from 24 September 2026, subject to continued compliance with the applicable requirements and conditions of the EDQM
f) Subsequent actual impact/corrective actions	Not applicable.